Future studies should consider longer term intervention in larger samples, with biomarkers such as BDNF and isoflavones to support and further confirm our observations, clarify potential causes of age- and gender-related differences in outcomes, as well as consider the effect on preclinical markers of Alzheimer’s disease. This evidence concerns the gene BDNF and Alzheimer disease.